

Special Issue

The Role of Hepatic Insulin Clearance in Obesity and Type 2 Diabetes

Message from the Guest Editors

The global prevalence of obesity and type 2 diabetes is rising at an alarming rate. Over the past decade, studies have demonstrated the significant role of insulin clearance in the obesity and pathogenesis of type 2 diabetes. It is well established that diminished hepatic insulin clearance leads to an elevated secretion of insulin into the systemic circulation, consequently resulting in hyperinsulinemia. Prolonged hyperinsulinemia can further exacerbate beta cell function, ultimately promoting type 2 diabetes. Nevertheless, the precise mechanisms and the role of insulin clearance in the obesity and pathogenesis of type 2 diabetes remain elusive. This Special Issue aims to present recent data related to and insights into the role of insulin clearance in obesity and the pathogenesis of type 2 diabetes. The scope extends to investigations in animal models as well as human subjects, plus new methods measuring lipidomics, metabolomics, or biomarkers capable of identifying changes caused by reduced or enhanced insulin clearance. Overall, the objective is to offer a comprehensive exploration of this critical element of study.

Guest Editors

Dr. Morvarid Kabir

Department of Medicine, Diabetes and Aging Center, Los Angeles, CA 90048, USA

Dr. Richard N. Bergman

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

Deadline for manuscript submissions

closed (31 January 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/194868

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-
Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).